Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen.
Determinations by immunologic methods of histidine-rich glycoprotein (HRG) and plasminogen, were made in plasma samples collected during one normal or hormone induced cycle in 15 young, normal women and in 11 women using oral contraceptives with 30 micrograms ethinyl estradiol and 150 micrograms levo-norgestrel. The hormone group showed an increase in plasminogen level to about 150% of normal, while the concentration of HRG was decreased to about 75% of normal. This resulted in a considerable relative increase in the concentration of free plasminogen in the hormone group (calculated from the equilibrium: HRG . plasminogen in equilibrium HRG + plasminogen, using KD = 1.0 microM), representing a doubling of that in the normal group. Hence, more plasminogen is available for binding to fibrin and activation in the hormone group.
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D009644:Norgestrel / Q000008:administration & dosage*; D010958:Plasminogen / Q000378:metabolism*; D011506:Proteins; D013923:Thromboembolism / Q000097:blood; D000099053:Histidine-Rich Glycoprotein
D006023:Glycoproteins; D011506:Proteins; D000099053:Histidine-Rich Glycoprotein; D009644:Norgestrel; D004997:Ethinyl Estradiol; D010958:Plasminogen